SK63499A3 - Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia - Google Patents

Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia Download PDF

Info

Publication number
SK63499A3
SK63499A3 SK634-99A SK63499A SK63499A3 SK 63499 A3 SK63499 A3 SK 63499A3 SK 63499 A SK63499 A SK 63499A SK 63499 A3 SK63499 A3 SK 63499A3
Authority
SK
Slovakia
Prior art keywords
plasmid
nucleic acids
encoding
ires
adenovirus
Prior art date
Application number
SK634-99A
Other languages
English (en)
Slovak (sk)
Inventor
Patrick Benoit
Nicolas Duverger
Didier Rouy
Sandrine Seguret
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of SK63499A3 publication Critical patent/SK63499A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK634-99A 1996-11-15 1997-11-13 Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia SK63499A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9613969A FR2755975B1 (fr) 1996-11-15 1996-11-15 Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
PCT/FR1997/002043 WO1998022606A1 (fr) 1996-11-15 1997-11-13 Adenovirus recombinants bicistroniques pour le traitement de pathologies liees aux dyslipoproteinemies

Publications (1)

Publication Number Publication Date
SK63499A3 true SK63499A3 (en) 2000-05-16

Family

ID=9497670

Family Applications (1)

Application Number Title Priority Date Filing Date
SK634-99A SK63499A3 (en) 1996-11-15 1997-11-13 Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia

Country Status (14)

Country Link
EP (1) EP0941355A1 (no)
JP (1) JP2001506488A (no)
KR (1) KR20000053320A (no)
AU (1) AU721654B2 (no)
BR (1) BR9712957A (no)
CA (1) CA2271437A1 (no)
CZ (1) CZ170399A3 (no)
FR (1) FR2755975B1 (no)
HU (1) HUP9904500A3 (no)
IL (1) IL129823A0 (no)
NO (1) NO992260L (no)
SK (1) SK63499A3 (no)
WO (1) WO1998022606A1 (no)
ZA (1) ZA9710271B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323112A1 (en) * 1998-03-16 1999-09-23 Introgen Therapeutics, Inc. Multigene vectors
AU7769800A (en) * 1999-08-10 2001-03-05 Develogen Ag Fur Entwicklungsbiologische Forschung Gene transfer combination vectors, method for the production and utilization thereof
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
AU4764801A (en) * 2000-03-24 2001-10-08 Calydon Inc Cell-specific adenovirus vectors comprising an internal ribosome entry site
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US7179659B2 (en) 2001-04-02 2007-02-20 Agilent Technologies, Inc. Sensor surfaces for detecting analytes and methods of use
EP2987499B1 (en) * 2011-08-08 2019-05-08 Allergan Pharmaceuticals International Limited Method for dissolution testing of solid compositions containing digestive enzymes
EP4019641A4 (en) * 2019-08-19 2022-12-21 Nanjing Novel Biotechnology Co., Ltd. REPLICATIVE ONCOLYTIC ADENOVIRUS TO REGULATE LIPID METABOLISM AND ITS UTILIZATION

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003143A1 (en) * 1991-08-07 1993-02-18 Anderson W French Retroviral vectors containing internal ribosome entry sites
GB9125896D0 (en) * 1991-12-05 1992-02-05 Almond Jeffrey W Bicistronic viruses
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
WO1996013597A2 (en) * 1994-10-28 1996-05-09 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
FR2731710B1 (fr) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique

Also Published As

Publication number Publication date
WO1998022606A1 (fr) 1998-05-28
FR2755975A1 (fr) 1998-05-22
KR20000053320A (ko) 2000-08-25
EP0941355A1 (fr) 1999-09-15
HUP9904500A2 (hu) 2000-05-28
AU5125298A (en) 1998-06-10
BR9712957A (pt) 2000-02-01
CA2271437A1 (fr) 1998-05-28
FR2755975B1 (fr) 1999-05-07
CZ170399A3 (cs) 1999-08-11
IL129823A0 (en) 2000-02-29
JP2001506488A (ja) 2001-05-22
NO992260D0 (no) 1999-05-10
HUP9904500A3 (en) 2002-01-28
NO992260L (no) 1999-05-10
AU721654B2 (en) 2000-07-13
ZA9710271B (en) 1998-08-21

Similar Documents

Publication Publication Date Title
JP3672494B2 (ja) 機能的ゲノム適用にライブラリーを使用される遺伝子機能に関する高度処理能力スクリーニング法
KR100403708B1 (ko) 재조합아데노-수반바이러스(aav)제조방법및이의용도
JP2019520391A (ja) 網膜変性を処置するためのｃｒｉｓｐｒ／ｃａｓ９ベースの組成物および方法
US20030143209A1 (en) Targeted adenovirus vectors for delivery of heterologous genes
EP1083231A1 (en) Smooth muscle cell promoter and uses thereof
JP2021533795A (ja) アデノ随伴ウイルスの形質導入効率を調節するための組成物および方法
SK63499A3 (en) Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia
US20060257371A1 (en) Adenoviral vectors for treating diseases
SK124897A3 (en) Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy
AU770005B2 (en) Selective regulation of adenovirus production
JP2013526840A (ja) 組み換えブチリルコリンエステラーゼおよびその切断型
CA2323235A1 (en) Adenoviral vectors for treating disease
CZ163399A3 (cs) Rekombinantní vektor pro cílenou a indukovanou expresi genů a farmaceutický přípravek obsahující takový vektor
US20130210898A1 (en) Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
WO2001002540A2 (en) Adenoviral vectors for treating disease
US20130164262A1 (en) Recombinant Viruses and their Use for Treatment of Atherosclerosis and Othe Forms of Coronary Artery Disease and Method, Reagent, and Kit for Evaluating Susceptibiity to Same
MXPA99004301A (es) Adenovirus recombinantes bicistronicos para el tratamiento de patologias relacionadas a las dislipoproteinemias
US20240141383A1 (en) Viral vector constructs incorporating dna for inhibiting toll like receptors and methods of using the same
van Winkel CRAd with capsid incorporated mesothelin for higher anti-tumor immunization
Santa Maria Development of gene therapy to deliver the receptor-specific rhTRAIL DHER variant to induce apoptosis in activated Hepatic Stellate Cells for the treatment of Liver Fibrosis
Fox Clinical Applications of Gene Therapy: Cardiovascular Disease